Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Caserta, Italy.
Inserm, BMGICU, 1035, University of Bordeaux, Bordeaux, France.
Mol Biol Rep. 2020 Jun;47(6):4875-4878. doi: 10.1007/s11033-020-05512-5. Epub 2020 May 14.
Zbtb7a is a transcription factor whose dysfunction is correlated to the development of several types of cancer, including hepatocellular carcinoma (HCC). It generally acts as a repressor of transcription downregulating the expression of several target genes including oncosuppressors ARF and Rb. In this study, Zbtb7a was found to suppress the expression of miR-125a, an oncosuppressive miRNA that is often downregulated in HCC. This effect is mediated by the binding of the transcription factor to a regulatory sequence in the promoter of the transcription unit of miR-125a located 14 bp upstream of the transcription start site. Consistent with this observation, the analysis of 370 HCC samples showed an upregulation of Zbtb7a compared to 50 normal liver tissues and a reverse correlation with miR-125a expression. These data suggest that miR-125a may support the oncogenic potential of Zbtb7a.
Zbtb7a 是一种转录因子,其功能障碍与多种癌症的发生有关,包括肝细胞癌(HCC)。它通常作为转录抑制剂发挥作用,下调包括肿瘤抑制因子 ARF 和 Rb 在内的几个靶基因的表达。在这项研究中,发现 Zbtb7a 抑制了 miR-125a 的表达,miR-125a 是一种肿瘤抑制 miRNA,在 HCC 中经常下调。这种效应是通过转录因子与位于转录起始位点上游 14bp 的 miR-125a 转录单元启动子中的调节序列结合介导的。与这一观察结果一致,对 370 个 HCC 样本的分析显示,与 50 个正常肝组织相比,Zbtb7a 上调,与 miR-125a 表达呈负相关。这些数据表明,miR-125a 可能支持 Zbtb7a 的致癌潜能。